Federal officials are now prohibited from requiring medically frail individuals to demonstrate exactly how their conditions prevent them from working 80 hours a month. This significant legal development occurs as the nation navigates the complexities of the One Big Beautiful Bill Act, a major
Legal experts are closely watching the University of Kentucky case to see if contract pharmacies will be held accountable for their role in the 340B ecosystem. This high-stakes legal battle, which emerged from a federal lawsuit filed by the University of Kentucky, centers on allegations that CVS
A Texas municipality recently reported that its employee health plan exceeded its projected annual budget by 40 million dollars due to the financial pressures created by the new law. This significant fiscal overage serves as a harbinger for a nationwide trend where the costs of implementing the No
Approximately 87% of oncology practitioners believe that the current systems for appealing insurance denials are neither reasonable nor adequate for patient needs. This startling statistic underscores the motivation behind West Virginia’s recent enactment of House Bill 4965, a transformative piece o
Senate Bill 13 codifies a tiered discount system designed to protect middle-income families from the predatory nature of mounting medical debt. This legislation represents a pivot point for Delaware’s healthcare landscape, as the state moves aggressively to regulate the financial practices of n
Regulatory innovation allows the Centers for Medicare & Medicaid Services to modernize payment models, but the agency lacks the authority to fix fundamental instabilities in the law. This inherent tension between administrative flexibility and statutory rigidity defines the current landscape of
While the demand for affordable semaglutide and tirzepatide surges, the FDA’s findings at a Texas facility highlight the hidden risks of unregulated manufacturing. The pharmaceutical landscape in 2026 continues to be shaped by the immense popularity of GLP-1 receptor agonists, which has created a m
The FDA's focus on teleoperated systems acknowledges the unique risks inherent in having a software interface sit between the surgeon's hand and the patient's tissue. This realization marks a transformative moment in medical device oversight, as the agency moves to solidify the
The ILR ECG Analyzer operates in the cloud to re-evaluate signals that have already been flagged by a device’s internal manufacturer-specific filtering system. This landmark achievement follows the U.S. Food and Drug Administration granting 510(k) clearance to the next-generation software, marking a
By activating both natural killer cells and T-cells, Anktiva creates a targeted immune environment that helps preserve the bladder while effectively managing aggressive urothelial carcinoma. This specialized immunotherapy represents a critical evolution in the treatment of non–muscle-invasive b
